TelewellnessMD® provides consulting and program recommendations for general health, age management, nutrition and other wellness healthcare needs through an online platform and network of wellness medical providers. Trim® Nutrition’s product line includes vitamins, supplements and protein shakes manufactured in CGMP facilities and proprietary nutrient injections compounded in a certified licensed pharmacy using the highest quality ingredients. Headquartered in Clearwater, Florida, Trim® Nutrition’s clinical staff of physicians, pharmacists, registered nurses, and research and development specialists are dedicated to the mission of Making Bodies Better™.
Meanwhile, more Phase II clinical studies are planned for the next 12 months including a study examining the efficacy of oral administration, which has been shown to be effective in laboratory animals. This will be followed by a weight loss study. Confirmation of the age-effect will also be sought. Metabolic aims to start a two-year Phase III studies program in 2003, which would not place final FDA approval before 2005.
Growth hormone releasing peptide (GHRP) 2 is a type of peptide therapeutic that mimics the effects of ghrelin, the “hunger hormone”. Ghrelin is a hormone that helps regulate appetite as well as energy distribution and rate of use, or metabolism. In the 1980’s, ghrelin was discovered to be the body’s natural ligand (or binding molecule) of the GHRP receptor in the anterior pituitary. This was a significant discovery, as it highlighted the role of ghrelin in hGH secretion and growth regulation. Modern biotechnology has used this knowledge to develop peptides that can be administered to mimic ghrelin’s hGH stimulation, but in a more targeted fashion. GHRP 2 is one such peptide, stimulating hGH secretion by 7-15 times, increasing appetite and meal initiation, while also decreasing fat mass and cholesterol. GHRP 2 is ideal for patients who are hypercatabolic, due to critical illness, cancer, AIDS, etc. It should be noted that GHRP 2 can also increase levels of prolactin, aldosterone, and cortisol.
If your unaccompanied goal is huge loss, it’s regularly best to skulk the act with regard to of GHRP products (GHRP-6, GHRP-2 or Hexarelin) being they gave a pink slip stimulate feel a dearth of and/or am a dealer of strength cortisol, both of which boot be counterproductive to immense burning. Ipamorelin, on the other laborer makes a great addition for it has no marching to a different drummer side chattels personal and increases GH secretion ultimately more, providing the applied force for drastic reductions in fat.
To really test the health benefits of drinking collagen peptides, I vowed to take it every day for two weeks. I opted for Vital Proteins Unflavored Grass-Fed Collagen Peptides in the blue tub. I got the 20-ounce tub and a box of the stick packs, which were perfect for when I went out of town. I stuck with one scoop from the tub for 35 calories, 9 grams of protein, and 10 grams of collagen (this was the same serving size in the stick packs).
Within all clinical trials the subjects underwent physical examination. The vital signs were observed, laboratory parameters were analyzed (hematology; biochemistry, urinalysis, lipid analysis), and ECG were measured before and after treatment (or in between and follow-up depending on the duration of the study). All subjects were interviewed at each visit with regard to any adverse events (AEs) they had experienced since the previous visit. The causality of AEs (namely their relationship to trial treatment) was assessed by the Principal Investigator. Special attention was made to on the evaluation of Serious Adverse Events (SAE).
The increase in GH secretion due to IPAMORELIN (and other GHRP) leads to an increase in IGF-1 (thought to be the anabolic mechanism of GH).  As we get older GH and subsequently IGF-1 decrease substantially.  This decline is thought to be one of the major causes of the ageing process.  By increasing these levels again there is increased collagen synthesis, promotion of lean muscle mass, bone strength, improved healing capability, improved sleep cycle, increased energy, repair and regeneration of internal organs, strengthening of joints/cartilage/connective tissue, and anti ageing effects on the skin. 
In the first dose-escalating study (METAOD001) 15 healthy male subjects received 3 single dosages of AOD9604 and placebo as single dosages each separated by a 7-day washout period (range 25 to 400 µg/kg bodyweight; single IV infusion doses over 20 minutes). One subject terminated the study due to personal reasons, 14 subjects completed the study. In total twenty-nine AEs were reported by twelve subjects during the study. No SAEs occurred during this study. The most common AEs reported during the study were headache (6 times). The remainder were related to fatigue (4), hypoglycemia unspecified (3), dizziness (3), nasopharyngitis (2), cough (2) and lethargy, tonsillitis, abdominal pain unspecified, application site reaction unspecified, sore throat unspecified, injection site bruising, rhinitis seasonal, anorexia, injection site pain, all with an incidence of 1. None of the AEs were of severe intensity. The majority of AEs were mild in intensity with possible relationship to study treatment, equally distributed between the various concentrations of AOD9604 and placebo treatment. The adverse event profile was similar following administration of all treatments.
When it comes to losing weight, no matter how little amount, it’s an uphill struggle…all the way! Using peptides correctly will provide surprisingly good results if the user can also put in some effort from the very start. Just by reducing your food and calorie drinks along with some daily exercise will soon reward you with a noticeable decrease in weight and fat loss.
Results: AOD 9604 had no effect on serum IGF-1 levels, which confirms the hypothesis that AOD 9604 does not act via IGF-1. Results of oral glucose tolerance test demonstrated that, in contrast with hGH, AOD 9604 has no negative effect on carbohydrate metabolism. There were no anti-AOD 9604 antibodies detected in any of the patients selected for antibody assay. In none of the studies did a withdrawal or serious adverse event occur related to intake of AOD 9604.
•Avoid eating/drinking anything with calories for three (3) hours either side of your injection. •Try to make all your meals throughout the day high protein, low fat and low carbohydrates (eg. meat/fish with vegetables/salad). •Have as few meals as possible during the day as periods of fasting have been shown in many studies to improve fat loss and also longevity (i.e. eating less will make you live longer).
But IGF-1 injections may soon be a thing of the past. Future use of IGF-1 will no doubt involve gene therapy, which directly targets genes that produce IGF-1 in muscle, usually by attaching specific gene activators to an inactive virus or vector that then enters into muscle cells. Studies in mice show that a procedure like this can cause  a 15% increase in muscle mass, along with a 14% increase in strength. Gene therapy in old mice has been shown to cause to a 27% increase in strength, along with regeneration of aging muscle. In one mouse study, the IGF-1 gene was placed in the animals’ glutes and calves, which resulted in up to a 115% increase in muscle-cross-sectional area.
The amazing effects of HCG on the hypothalamus were discovered by Dr. Albert T. W. Simeons in 1954, who observed that malnourished women tend to give birth to healthy babies with normal birth weights. Dr. Simeons concluded that women are able to do this because the HCG hormone that their bodies naturally produced during pregnancy helped their bodies to metabolise subcutaneous fat. hCG released by the embryo also helps women with weight redistribution (helps prevent uneven deposits of weight on thighs, abdomen, hips etc) and therefore women concerned with hormonal weight gain are ideal candidates for this diet.
Ghrelin and GH secretagogues, including GH-releasing peptide (GHRP)-6, stimulate food intake and adiposity. Because insulin modulates the hypothalamic response to GH secretagogues and acts synergistically with ghrelin on lipogenesis in vitro, we analyzed whether insulin plays a role in the metabolic effects of GHRP-6 in vivo. Streptozotocin-induced diabetic rats received saline, GHRP-6, insulin, or insulin plus GHRP-6 once daily for 8 wk. Rats receiving saline suffered hyperglycemia, hyperphagia, polydipsia, and weight loss. Insulin, but not GHRP-6, improved these parameters (P < 0.001 for all), as well as the diabetes-induced increase in hypothalamic mRNA levels of neuropeptide Y and agouti-related peptide and decrease in proopiomelanocortin. Cocaine amphetamine-related transcript mRNA levels were also reduced in diabetic rats, with GHRP-6 inducing a further decrease (P < 0.03) and insulin an increase. Diabetic rats receiving insulin plus GHRP-6 gained more weight and had increased epididymal fat mass and serum leptin levels compared with all other groups (P < 0.001). In epididymal adipose tissue, diabetic rats injected with saline had smaller adipocytes (P < 0.001), decreased fatty acid synthase (FAS; P < 0.001), and glucose transporter-4 (P < 0.001) and increased hormone sensitive lipase (P < 0.001) and proliferator-activated receptor-gamma mRNA levels (P < 0.01). Insulin normalized these parameters to control values. GHRP-6 treatment increased FAS and glucose transporter-4 gene expression and potentiated insulin's effect on epididymal fat mass, adipocyte size (P < 0.001), FAS (P < 0.001), and glucose transporter-4 (P < 0.05). In conclusion, GHRP-6 and insulin exert an additive effect on weight gain and visceral fat mass accrual in diabetic rats, indicating that some of GHRP-6's metabolic effects depend on the insulin/glucose status.
Statistical analysis was performed using SPSS version 14.0 (SPSS, Chicago, Ill). The differences of gross morphological and histolopathological findings and lameness period among four groups were assessed using the Kruskal–Wallis test. The Mann–Whitney U test was used to compare the gross morphological and histolopathological findings and lameness period between two groups, and p-values <0.05 were considered statistically significant.
I was using MT II while using the 1st vial and lost 14 lbs in 10 days. Had to fly to Pittsburgh for a couple days and started 2nd vial with no MT II and dropped 8 more. I weighed yesterday upon completion of the 2nd vial with shoes and clothes on. Was very pleased with the results. I did a cycle of T3 prior to the frag and didnt do near as well and was fighting muscle loss, felt like crap ect.. Will be purchasing more, I use Southern Research on the peptides.

AOD9604 is a peptide fragment of the C-terminus of human growth hormone (Tyr-hGH177-191). It is prepared by solid phase peptide synthesis and contains an additional tyrosine residue at the N-terminal end that stabilizes the peptide. Investigation on the secondary structure of AOD9604 showed similarities to the homologous region in the naturally occurring hGH molecule [19]. Animal experiments confirmed the fat reducing potential of AOD9604, which seems to act directly on fat metabolism without influencing appetite. In genetically obese strains of rats and mice, AOD9604 was shown to affect body weight reduction, stimulation of lipolysis and inhibition of lipogenesis. Adverse effects, as seen in similar studies using intact hGH [18, 20, 21], were not observed with AOD9604 supplementation.
There’s never been a better formula to help you reach your weight loss goals with patented, clinically-proven, and all-natural ingredients. While being one of the most powerful formulas on the market, it’s the safest as well. The best part is each and every bottle is backed by a 90-day, 100% Money Back Guarantee, making Apidren completely RISK FREE! With these clinically proven ingredients and industry-leading money back guarantee, there’s no other diet supplement we would recommend! Read More
As in the previous study there were no clinically relevant changes observed in safety laboratory parameters 24 hours following administration of AOD9604 or placebo. Similarly, there were no clinically relevant changes in vital signs (blood pressure, radial pulse rate and temperature) or ECGs recorded at any of the scheduled time points up to 24 hours post dose. There were no significant changes in glucose or IGF-1 levels following AOD9604 treatment compared with placebo.
Another side effect of the CJC-1295 is acromegaly, since it helps in increasing the levels of the growth hormone. Acromegaly is a condition where extra growth hormone is released even after the internal organs and the skeleton have finished growing. This causes thickening of the skin, deepening of voice, enlargement of jaws, and slurring of speech. Another effect of acromegaly is the swelling of the soft tissue in the internal organs. This could result in the weakening of the muscles of the internal organs, like the heart. This was tested during the phase 2 testing of CJC-1295.
In June 2010, the National Drugs and Poisons Schedule Committee (NDPSC) considered the scheduling of paracetamol in combination with ibuprofen. Paracetamol preparations containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine, effervescent agents or guaiphenesin) in packs of 25 or less were exempt from scheduling. However, when these preparations were combined with another therapeutically active ingredient they became Schedule 2. The NDPSC considered that the Schedule 2 entry remained appropriate, but noted the possibility that more robust evidence of additional risk could come to light through any application for product approval with the Therapeutic Goods Administration. The delegate confirmed the NDPSC's decision and the reasons for the decision in August 2010.

The most common goal of people in the health and fitness world is to lose weight. Not only do hundreds of millions of people go on diets to try and lose weight every year, but they want to lose weight as fast as possible. It’s no wonder the weight loss industry is a $20 billion industry, with the sales of books, diet drugs, and weight-loss surgeries fueling revenue as people try and lose unwanted weight once and for all.
Up to the date of this paper, six clinical trials (three single dose studies and three multiple dose studies from which 2 were long-term studies) have been conducted with AOD9604. In none of the three acute dose-escalating studies (METAOD001 - METAOD003) were there reported any AEs related to the intake of AOD9604, withdrawals from the study caused by AOD9604 or SAEs reported. No treatment related differences were identified upon administration of AOD9604 by IV injection (25 µg - 400 µg/kg bodyweight) or orally (9 mg - 54 mg). Treatment with AOD9604 as a single dosage had no effect on physical examination, vital signs, laboratory parameters, ECG, blood glucose and IGF-1 levels, with results indistinguishable from placebo.

Because these peptides are so numerous and variable in structure, their effects are likewise varied and wide-ranging. One class of these peptides are known as growth hormone secretagogues, and cause the secretion of one’s own, natural hGH in the body. These peptides have been shown to be very useful in the treatment of age-related conditions, osteoporosis, obesity, and various chronic inflammatory diseases, and have several advantages over traditional hGH administration.
In the first dose-escalating study (METAOD001) 15 healthy male subjects received 3 single dosages of AOD9604 and placebo as single dosages each separated by a 7-day washout period (range 25 to 400 µg/kg bodyweight; single IV infusion doses over 20 minutes). One subject terminated the study due to personal reasons, 14 subjects completed the study. In total twenty-nine AEs were reported by twelve subjects during the study. No SAEs occurred during this study. The most common AEs reported during the study were headache (6 times). The remainder were related to fatigue (4), hypoglycemia unspecified (3), dizziness (3), nasopharyngitis (2), cough (2) and lethargy, tonsillitis, abdominal pain unspecified, application site reaction unspecified, sore throat unspecified, injection site bruising, rhinitis seasonal, anorexia, injection site pain, all with an incidence of 1. None of the AEs were of severe intensity. The majority of AEs were mild in intensity with possible relationship to study treatment, equally distributed between the various concentrations of AOD9604 and placebo treatment. The adverse event profile was similar following administration of all treatments.
There’s never been a better formula to help you reach your weight loss goals with patented, clinically-proven, and all-natural ingredients. While being one of the most powerful formulas on the market, it’s the safest as well. The best part is each and every bottle is backed by a 90-day, 100% Money Back Guarantee, making Apidren completely RISK FREE! With these clinically proven ingredients and industry-leading money back guarantee, there’s no other diet supplement we would recommend! Read More

As an athlete, you can also increase your dosage cycle for a period of 12 to 16 weeks at a time, to maximize your gains. Do so gradually if you opt to go this route. Make sure you increase your daily dosage (1 to 2 doses per day, etc.) gradually. Start off with lower dosage levels as well, and see how it interacts with your body. You don’t want to experience withdrawal, nor do you want to experience negative side effects when using Ipamorelin for longer dosage cycles. So, make sure you monitor your progress, see how you feel as you go, and make notes if/when you do experience negative side effects, so you can balance down to the proper dosage levels.
IGF-1 also increases the activity of muscle protein synthesis and the activity of muscle stem cells (also called satellite cells) for repair of damaged muscle. This is probably why intense weight training is one primary stimulus for a natural release of IGF-1 in muscle. As a matter of fact, exercise researchers have found that systemic IGF-1 normally produced in the liver isn’t even required for this type of muscle repair, as other IGF-1 forms produced by your own muscles during and post-exercise allows for adequate muscle tissue repair.
Amongst its metabolic effects, hGH can induce inhibition of lipoprotein lipase activity in adipose tissue, stimulating lipolysis in adipocytes, which results in the reduction of fat cell mass [4-7]. Moreover, a correlation has been found between adiposity and the reduced circulating levels of hGH [8]. When applied systemically, hGH reduces body fat mass and influences fat distribution [9]. Therefore, treatment with hGH should theoretically have a positive impact on obesity. However, long term treatment with hGH is associated with various health risks, including glucose intolerance and insulin resistance, diabetes, acromegaly, cancer, edema, and hypertension [10-13].

Overall, there were no AEs that were deemed to be “definitely related” to the study treatment. The percentage of AEs that were deemed to be “probably” or “possibly related” to study treatment was similar among all treatment groups including placebo. The most common classes of AE deemed to be “probably” or “possibly”related to study treatment were gastrointestinal disorders (5.2% overall) and nervous system disorders (4.9% overall).


Finally, patients deficient in growth hormone who get IGF-1 injections have shown increased rates of fat loss and fat oxidation. One theory for this is that, as you’ve just learned, IGF-1 can suppress circulating insulin, which would allow more burning of fatty acids from fat cells. This makes sense, since we do know that fat cells contain IGF-1 receptors, and this means that IGF-1 can interact with fat cells.
One combination of natural supplements that boost IGF-1 with no injections required would simply be a one-two combo of whey protein and colostrum. Throw small bits of natural dairy into the mix and you’ve got a pretty potent trilogy for not just increasing IGF-1, but also all the fat loss, lean muscle gain, and cellular repair mechanisms that accompany a surge in growth hormone.
recently studies found that in the process of destroying the fat cells, it shook stem cells which are inside the fat cells giving rise to new found REGENERATIVE POWERS of AOD. It works well at regenerating ligaments after significant damage and muscle repair, by increasing cartilage and collagen production in your joints. It has also been seen to improve bone density which can have positive effects on osteoporosis.
The discovery of the role of Tβ4 in the process of immune regulation has lead to its use as a valuable therapeutic agent. Tβ4 has been used in the treatment of HIV, AIDS, Influenza, colds, and various infections. It has been utilized in the management of various inflammatory conditions, as well as part of treatment following heart attack due to its cardio and neuroprotective effects.

In addition, scientists have observed that those who supplemented with IGF-1 experienced a preponderance of new brain cell growth and new muscle mass and new studies confirmed this to be true, even among individuals with both brain damage and muscle-wasting sarcopenia. Furthermore, research studies have found IGF-1 to increase feelings of youthfulness, improve well-being, and even to alleviate depression.
This particular peptide offers therapeutic benefits similar to those of hGH. CJC 1295 is a growth hormone releasing hormone (GHRH) analogue. In other words, it is a molecule that serves the same purpose as does GHRH—the hormone that stimulates the anterior pituitary to release hGH. However, unlike GHRH, which has a half-life of only minutes after IV administration, CJC 1295 is able to remain active in the body for extended periods due to its ability to bind to a protein in the blood known as albumin and avoid degradation by various enzymes. CJC 1295 increases an important growth factor, IGF-1, in addition to hGH, leading to fat loss, lean muscle growth, and enhanced sleep.
Both paracetamol and caffeine are regarded as being well tolerated when used at therapeutic doses and there is a low risk of serious expected or serious unexpected adverse events with these products when taken either alone or in combination. Clinical data demonstrate that paracetamol combined with caffeine significantly out performs paracetamol alone. Paracetamol/caffeine formulations are well established globally. Such formulations are marketed in over 90 countries and have been available unscheduled ranging from 14 years to 25 years. Cumulative post-marketing experience to date with the sponsor’s paracetamol/caffeine combination products is estimated to be in excess of 488 million patients and has revealed no adverse safety signals or reasons for concern with the use of this product in an open sale environment.
Conclusions: Subcutaneous administration of CJC 1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 ug/ kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC 1295 as a therapeutic agent.
AOD9604 is also known as the ANTI OBESITY DRUG and has been found to target abnormal fat stores (e.g. buttocks, knees, chin, abdomen, and flabby arms). AOD is a Peptide fragment of hGH which is a fat loss and healing properties. Because AOD is a fragment of the C-terminus of hGH, it contains the fat reducing capability of hGH, but does not adversely affect your blood sugar levels or your IGF-1 levels.
Resting plasma concentrations of mature BNP and Nt‐proBNP were 14±3 pg/mL and 42±9 pg/mL before gastric bypass surgery and increased to 32±5 pg/mL and 107±20 pg/mL (increased by 50% and 31%), respectively (P=0.0009 and 0.0001) after the surgery. Circulating BNP and Nt‐proBNP concentrations during saline infusion were also higher after surgery compared with before surgery (Figures 2A and 2B; P<0.0001). The saline infusion itself was not associated with an increase in BNP or Nt‐proBNP levels at either visit (P=0.65 and 0.60, respectively).

After the commencement of the active treatment 88.9% of subjects experienced at least one AE, whereby the distribution was similar in the 5 AOD9604 groups and the placebo group. There was a higher incidence (48.4%) of nervous system disorders (mainly headache, 42.6%), gastrointestinal disorders (30.4%, mainly diarrhea unspecified, 9.0%) and infections and infestations (45.3%), than seen before the commencement of active treatment. The distribution of the intensity of AEs was similar across all treatment groups. The percentage of AEs that deemed to be possibly or probably related to the study medication was similar across all treatment groups, including placebo.
Athletes will greatly benefit from using Ipamorelin. For example, if you use CJC 1295 along with Ipamorelin, the results are going to be even greater. HGH increase will result in greater muscle mass levels, less time for muscle mass to develop, and increased levels of lean muscle tissue. The more peptides your body produces, the greater your lean muscle mass is going to be. And, over time, with gradual increases in HGH, you are going to realize a leaner, more muscular definition to your body.
The four groups showed different gross morphological damage and histopathological changes in the cartilage of the lateral part of the femoral condyle (Figure 3). Complete disorganization of articular cartilage with apparent cloning of chondrocytes in the transitional and radial zones was evident in Group 1 (Figures 3-A,E,I). Abnormal gross morphological and histopathological changes such as fibrillated and irregular cartilage surfaces, disappearance of surface-layer cells, and slightly diffused cell growth in the transitional and radial zones were observed in Group 2 (Figures 3-B,F,J). Erosion of the articular cartilage, cleft, and cell cloning in the transitional and radial zones were noted in Group 3 (Figures 3-C,G,K). Softening of articular cartilage and surface irregularities were noted in Group 4 (Figures 3-D,H,L).

Background: The human growth hormone (hGH) has properties making it a potential candidate to treat obesity, however safety issues limit its long-term use. AOD9604 is a peptide fragment of the C-terminus of hGH (Tyr-hGH177-191), which harbors the fat reducing activity of hGH, without its negative effects. In this paper the safety data of AOD9604 obtained in clinical trials are summarized.


"Paracetamol is used worldwide for its analgesic and antipyretic actions and has been available in Australia since 1956. Caffeine is a stimulant and acts as an analgesic adjuvant, whereby it augments the analgesic effects of pain relievers such as paracetamol. The combination of paracetamol/caffeine (2x500mg/65mg) is indicated for temporary relief of pain and discomfort associated with headaches, tension headaches, osteoarthritis, arthritis, cold and flu symptoms, toothache, dental procedures, muscular aches, sore through and period pain. It also reduces fever.
All peptide injections are compounded under strict sterile conditions according to USP 797 Standards. We use peptides obtained from a GMP certified manufacturer which are all over 99% pure and endotoxin tested and proven to be safe. We also perform sterility tests on all peptide preparations supplied which ensures the quality and safety of our products.
×